The biological revolution - Towards a mechanistic understanding of the impact of diet on cancer risk

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 551, Issue 1-2, 2004, Pages 43-49

  Mathers, John C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Aspirin; Cancer; Diet; Epigenetics; Nutrigenomics; Single nucleotide polymorphism

Indexed keywords

ACETYLSALICYLIC ACID;

ADENOMA; CANCER; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DATA BASE; DIET; DNA DAMAGE; FEEDING BEHAVIOR; GENE EXPRESSION; GENE INTERACTION; GENE MAPPING; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOME; GENOMICS; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REDUCTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANTICARCINOGENIC AGENTS; ASPIRIN; CHEMOPREVENTION; DIET; DNA REPAIR; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 3042679910     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2004.01.011     Document Type: Review

References (51)

1. J.C. Mathers, Nutrients and apoptosis, in: J. Zempleni, H. Daniel (Eds.), Molecular Nutrition, CABI Publishing, Wallingford, 2003, pp. 73-89.
2. Momparler R.L. Cancer epigenetics. Oncogene. 22:2003;6479-6483
3. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim. Biophys. Acta. 1332:1997;F127-F147
4. Kaplan K.B., Burds A.A., Smedlow J.R., Bekir S.S., Sorger P.K., Nathe I.S. A role for the adenomatous polyposis coli protein in chromosome segregation. Nat. Cell Biol. 3:2001;429-432
5. Fodde R., Kuipers J., Rosenberg C., Smits R., Keilman M., Gaspar C., van Es J.H., Breukel C., Wiegant J., Giles R.H., et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat. Cell Biol. 3:2001;433-438
6. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
7. Rajagopalan H., Nowak M.A., Vogelstein B., Lenguaer C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer. 3:2003;695-701
8. Sieber O.M., Heinimann K., Tomlinson I.P.M. Genomic instability - the engine of tumorigenesis. Nat. Rev. Cancer. 3:2003;701-708
9. Balmain A., Gray J., Ponder B. The genetics and genomics of cancer. Nat. Genet. Suppl. 33:2003;238-244
10. Doll R., Peto R. The causes of cancer: quantitative estimates of the avoidable risks of cancer in the United States. J. Natl. Cancer Inst. 66:1981;1191-1308
11. Riboli E., Kaaks R. The EPIC project: rationale and study design. Int. J. Epidemiol. 26(Suppl. 1):1997;S6-S14
12. Bingham S.A., Day N.E., Luben R., Ferrari P., Slimani N., Norat T., Clavel-Chapelon F., Kessse E., Nieters A., Boeing H., Tjønneland A., Overad K., Martinez C., Dorronsoro M., Gonzalez C.A., Keys T.J., Trichopolou A., Naska A., Vineis P., Tumino R., Krogh V., Bas Bueno-de-Mesquita H., Peeters P.H.M., Berglund G., Hallmans G., Lund E., Skeie G., Riboli E. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet. 361:2003;1496-1501
13. Bingham S.A., Luben R., Welch A., Wareham N., Khaw K.-T., Day N. Are imprecise methods obscuring a relationship between fat and breast cancer? Lancet. 362:2003;212-214
14. Khaw K.-T., Bingham S., Welch A., Luben R., Wareham N., Oakes S., Day N. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet. 357:2001;657-663
15. Baron J.A., Sandler R.S. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 51:2000;511-523
16. Bosetti C., Gallus S., La Vecchi C. Aspirin and cancer risk: an update to 2001. Eur. J. Cancer Prev. 11:2002;535-542
17. Sandler R.S., Halabi S., Baron J.A., et al. A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl. J. Med. 348:2003;883-890
18. Baron J.A., Cole B.F., Sandler R.S., et al. A randomised trial of aspirin to prevent colorectal adenomas. New Engl. J. Med. 348:2003;891-899
19. Barnes C.J., Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis Min mouse model with aspirin. Gastroenterology. 114:1998;873-877
20. Mahmoud N.N., Carothers A.M., Grunberger D., Bilinski R.T., Churchill M.R., Martucci C., Newmark H.L., Bertagnoli M.M. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery. 124:1998;225-231
21. Chiu C.H., McEntee M.F., Whelan J. Discordant effect of aspirin and indomethicin on intestinal tumor burden in Apc (Min/+) mice. Prostaglandins Leukot. Essent. Fatty Acids. 62:2000;269-275
22. Min/+ towards the chemopreventive efficacy of dietary aspirin and curcumin. Br. J. Cancer. 88:2003;1480-1483
23. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809
24. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunderrs B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl. J. Med. 342:2000;1946-1952
25. Qiao L., Hanif R., et al. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem. Pharmacol. 55:1998;53-64
26. Menzel T., Schauber J., Kreth F., Kudlich T., Melcher R., Gostner A., Scheppach W., Lührs H. Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells. Eur. J. Cancer Prev. 11:2002;271-281
27. Martin C., Connelly A., Keku T.O., Mountcastle S.B., Galanko J., Woosley J.T., Schliebe B., Lund P.K., Sandler R.S. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 123:2002;1770-1777
28. Iizaki M., Furukawa Y., Tsunoda T., Akasi H., Ogawa M., Nakamura Y. Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem. Biophys. Res. Comm. 292:2002;498-512
29. Martinez M.E., O'Brien T.G., Filtz K.E., Babbar N., Yerushalmi H., Qu N., Guo Y., Boorman D., Einspahr J., Alberts D.S., Gerner E.W. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. PNAS. 100:2003;7859-7864
30. Guo Y., Harris R.B., Rosson D., Boorman D., O'Brien T.G. Functional analysis of human ornithine decarboxylase alleles. Cancer Res. 60:2000;6314-6317
31. Mohrenweiser H.W., Xi T., Vázquez-Matías J., Jones I.M. Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol. Biomark. Prevent. 11:2002;1054-1064
32. Goode E.L., Ulrich C.M., Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomark. Prevent. 11:2002;1513-1530
33. Wu X., Zhao H., Wei Q., Amos C.I., Zhang K., Guo Z., Qiao Y., Hong W.K., Spitz M.R. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis. 24:2003;505-509
34. Haga S.B., Khoury M.J., Burke W. Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat. Genet. 34:2003;347-350
35. Mathers J.C. Nutrition and cancer prevention: diet-gene interactions. Proc. Nutr. Soc. 62:2003;605-610
36. Beskow L.M., Burke W., Merz J.F., Barr P.A., Terry S., Penchaszadeh V.B., Gostin L.O., Gwinn M., Khoury M.J., Muin J. Informed consent for population-based research involving genetics. JAMA. 286:2001;2315-2321
37. Manson M.M. Cancer prevention - the potential for diet to modulate molecular signalling. Trends Mol. Med. 9:2003;11-18
38. Surh Y.-J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer. 3:2003;768-780
39. Müller M., Kersten S. Nutrigenomics: goals and strategies. Nat. Rev. Genet. 4:2003;315-322
40. Notterman D.A., Alon U., Sierk A.J., Levine A.J. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma and normal tissue examined by oligonucleotide arrays. Cancer Res. 61:2001;3124-3130
41. Williams E.A., Coxhead J.M., Mathers J.C. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc. Nutr. Soc. 62:2003;107-115
42. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature. 403:2000;41-45
43. Poirier L.A. The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J. Nutr. 132:2002;2336S-2339S
44. James S.J., Melnyk S., Pogribna M., Pogribny I.P., Caudill M.A. Elevation of S-adenosylhomocysteine and DNA hypomethylation: potential mechanism for homocysteine-related pathology. J. Nutr. 132:2002;2361S-2366S
45. Turner B.M. Cellular memory and the histone code. Cell. 111:2002;285-291
46. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. Suppl. 33:2003;245-254
47. Mathers J.C. Pulses and carcinogenesis: potential for the prevention of colon, breast and other cancers. Br. J. Nutr. 88(Suppl. 3):2002;S273-S279
48. T.P. Delaney, S. Uknes, Vernooij, J. Friedrich, K. Weymann, T. Negretto, T. Gaffney, M. Gut-Rella, H. Kessmann, E. Ward, J. Ryals, A central role for salicylic acid in plant disease resistance, Science 266 (1994) 1247-1250.
49. Arimura G., Ozawa R., Shimoda T., Nishioka T., Boland W., Takabayashi J. Herbivory-induced volatiles elicit defense genes in lima bean leaves. Nature. 406:2000;512-515
50. Lawrence J.R., Peter R., Baxter G.J., Robson J., Graham A.B., Patterson J. Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. J. Clin. Pathol. 56:2003;649-650
51. Janssen P.L., Hollmann P.C., Reichman E., Venema D.P., van Staveren W., Katan M.B. Urinary salicylate excretion in subjects eating a variety of diets shows that amounts of bioavailable salicylates in foods are low. Am. J. Clin. Nutr. 64:1996;743-747